Agile's Twirla Suffers Scathing Critique By US FDA Ahead Of Advisory Cmte.
Executive Summary
Agile's transdermal contraceptive will go before the Bone, Reproductive and Urologic Drugs Advisory Committee as it nears the end of its third review cycle, although the agency appears ready to issue another complete response letter before it even hears from the panel.
You may also be interested in...
Keeping Track Of User Fee Decisions And Filings: Adakveo, Brukinsa And Fetroja Mark Massive Week Of Novel Approvals
The latest news on US FDA user fee decisions and submissions to the agency.
Agile’s Twirla Heads To Advisory Committee: No Mystery Why
Contraceptive patch has had rocky regulatory path with US FDA. To Agile’s credit, the company pulls no punches in its shareholder filings in explaining the situation.
Keeping Track: Resubmissions For Tlando And Twirla NDAs, And A BTD For Pomalyst
The latest drug development news and highlights from our US FDA Performance Tracker.